MMP9 and neoplasm: Specific MMP-9 inhibitors, such as GS-5745 (Andecaliximab) [24, 25], are being tested in clinical trials in combination with chemotherapy or immune checkpoint inhibitors in order to block paracrine signaling and metastasis and to alter the immune microenvironment within the tumor.